NorthStar Medical Technologies has closed $100 million in secured financing, the company announced recently.

According to a release, the funds were managed by Oberland Capital Management, and the money will be used to increase domestic production capacity for the medical radioisotope molybdenum-99 (Mo-99), complete programs to improve the efficiency of the production of Mo-99, implement additional enhancements for the RadioGenix System and continue R&D activities.

“This financing agreement with Oberland Capital enables us to execute on our clearly defined strategy to build solid, sustainable momentum for NorthStar as a fully commercial enterprise,” NorthStar CEO Stephen Merrick said in a statement. “This funding provides NorthStar with the means to … expand production capacity for non-uranium based Mo-99, including the almost-complete 20,000-square foot expansion of our facility in Beloit.”

The company received $75 million at closing with the ability to draw the remaining $25 million prior to December 31, 2020.

NorthStar’s technology uses stable isotopes of molybdenum to produce Mo-99 domestically without incurring the concerns related to the management of toxic waste associated with Mo-99 production from enriched uranium.